Poor adherence and the subsequent development of drug resistance is one reason why HIV treatment can fail. A drug-resistant HIV strain is one which is less susceptible to the effects of one or more anti-HIV drugs.

Resistance: latest news

Resistance resources

  • Changing HIV treatment

    Talk to your doctor if you are concerned about any side-effects you are experiencing.If you are having problems taking your HIV treatment, it’s important to be honest...

    From: Factsheets

    Information level Level 2
  • Taking your HIV treatment (adherence)

    Taking your medication exactly as prescribed is key to HIV treatment working.As treatment is a long-term commitment, it’s important that your treatment suits your lifestyle.If you find...

    From: Factsheets

    Information level Level 2
  • Drug resistance

    It's important to always take your HIV treatment at the right times and in the right amounts. If you don't, HIV may become drug resistant.When...

    From: The basics

    Information level Level 1
  • An HIV treatment journey

    This illustrated leaflet shows the journey a lot of people go on with HIV treatment. However, each person’s situation is different. Your own circumstances may...

    From: The basics

    Information level Level 1
  • My drugs chart

    My drugs chart provides information on all the anti-HIV drugs currently licensed for use in Europe.Select your chosen drugs and drag them onto the area...

    From: My drugs chart

  • What is drug resistance?

    One of the possible consequences of not taking your HIV treatment properly is that your HIV will develop resistance to anti-HIV drugs. This section of the booklet provides...

    From: Booklets

    Information level Level 2
  • Resistance tests

    Blood tests are available which detect whether the HIV in your body is resistant to any anti-HIV drugs. It's recommended that you have a drug resistance test before...

    From: Booklets

    Information level Level 2
  • Taking your HIV treatment

    This booklet is a starting point for anyone who wants to know about treatment for HIV. It provides basic information about how HIV treatment works...

    From: Booklets

    Information level Level 2
  • Drug resistance

    HIV reproduces in the body very quickly, making billions of new viruses every day by replicating its genetic material. HIV is a retrovirus; retroviruses have an inherently high...

    From: HIV treatments directory

    Information level Level 4

Resistance in your own words

Resistance news from aidsmap

More news

Resistance news selected from other sources

  • New HIV therapy reduces virus, boosts immunity in drug-resistant patients

    Ibaluzimab, a CD4 receptor inhibitor and the first monoclonal antibody developed as an anti-HIV drug, was approved for treatment in the US for people with multiply drug-resistant HIV (MDR-HIV) last February. In the results of a phase III study published today, 83% of a group of patients with MDR-HIV achieved an undetectable viral load on ibaluzimab and 50% maintained this over six months. Details of this and another phase III study will be presented later htis year.

    18 hours ago | Science Daily
  • Reported 'PrEP Failure' in Thailand May Be a Missed Acute HIV Infection: Here's What You Need to Know

    The Infectious Diseases Society of America reported on June 29, 2018, that a new HIV acquisition had been found in a person using pre-exposure prophylaxis (PrEP). According to the journal article, a 28-year-old cisgender male in Thailand began using PrEP on March 16, 2016, after being verified HIV negative by a third generation antibody test. However the third generation antibody test available in this case has a window period of three to 12 weeks, with 3% of the population still testing HIV negative after 12 weeks. This is why clinical testing sites use RNA testing whenever possible, as the RNA test from May 13 did show positive for HIV while the third generation antibody test on the same day showed HIV negative.

    17 July 2018 | TheBody PRO
  • Low CD4 count in patients with HIV prolongs influenza viral shedding

    HIV-infected individuals with a low CD4 count experienced a longer duration of influenza virus shedding, according to findings published in The Journal of Infectious Diseases.

    11 June 2018 | Healio itj+ (requires free registration)
  • Computer Models Are Changing How We Craft HIV-AIDS Policies

    A computer modeling of AIDS-affected populations of sub-Saharan Africa has recently enabled the World Health Organization (WHO) to identify a cost-effective measure to address the increasing prevalence of drug-resistant HIV in the region.

    04 May 2018 | Healthcare Analytics News
  • World Health Organization Debunks Reports of New HIV Strain

    Respected world agencies are downplaying initial reports of a new strain of HIV found in the Philippines. The Joint United Nations Programme on HIV/AIDS (UNAIDS) and the World Health Organization (WHO) have both released statements that soundly reject recent initial media reports that warned their readers of a new, untreatable strain of HIV that has been identified in certain areas.

    13 April 2018 | HIV Plus
  • ARV stock-outs kill more Ugandans

    “Of recent, HIV drug stock-out is adding a lot of misery to us as service providers in the ART clinics because we get very few drugs from National Medical Stores (NMS) which is not enough for our patients. We keep on begging for drugs from nearby health centres. When patients spend long time without taking drugs, they develop resistance,” Dr Peter Andrew Kalema said.

    12 April 2018 | The Observer
  • Reported PrEP 'Failure' Most Likely a Lack of Proper Testing and Adherence

    When is a pre-exposure prophylaxis (PrEP) failure actually a provider failure? And how do we tell the difference? This was a question that came up at CROI 2018 after a poster presentation titled "Seroconversion on PrEP: A Protocol for Untangling Adherence versus Resistance Failure" sparked conversations and debates about how you distinguish an example of tenofovir/emtricitabine (Truvada) failing to protect an individual from acquiring HIV, versus a provider whose negligence and failure to follow Centers for Disease Control and Prevention (CDC) protocol may have put his or her patient at grave risk.

    21 March 2018 | The Body PRO
  • Statement of UNAIDS on news reports of a new HIV strain in the Philippines

    UNAIDS is concerned that media reports which make reference to HIV research in the Philippines are being interpreted as saying that there is a new and untreatable strain of the virus in the country. There is no new strain of HIV which has been found in the Philippines.

    21 March 2018 | UNAIDS Asia-Pacific
  • FDA approves new HIV treatment for patients who have limited treatment options

    Today, the U.S. Food and Drug Administration approved Trogarzo (ibalizumab-uiyk), a new type of antiretroviral medication for adult patients living with HIV who have tried multiple HIV medications in the past (heavily treatment-experienced) and whose HIV infections cannot be successfully treated with other currently available therapies (multidrug resistant HIV, or MDR HIV).Trogarzo is administered intravenously once every 14 days by a trained medical professional and used in combination with other antiretroviral medications.

    07 March 2018 | FDA
  • Infectious diseases doctor sounds an international alarm about HIV treatment resistance in the Philippines

    Dr. Edsel Salvana explains the global implications of treatment-resistant HIV in the Philippines.

    25 January 2018 | Science Speaks
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.